Key References in Infectious Diseases Pharmacotherapy
Identifieur interne : 005822 ( Main/Exploration ); précédent : 005821; suivant : 005823Key References in Infectious Diseases Pharmacotherapy
Auteurs : Richard H. Drew [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2004-11.
English descriptors
- Teeft :
- American college, Antibiotic, Antibiotic therapy, Antifungal, Antifungal susceptibility testing, Antifungal therapy, Antimicrobial, Antiretroviral, Antiretroviral agents, Article reviews, Asymptomatic bacteriuria, Aureus, Aureus infections, Azithromycin, Bacterial infections, Bacterial meningitis, Bacterial resistance, Candidiasis, Clinical pharmacy, Clinical trials, Complication rates, Critical care perspective, Cystic fibrosis, Dexamethasone, Diabetes mellitus, Disease epidemiology, Duke university, Fluoroquinolone, Fluoroquinolone resistance, Food animals, Fungal infections, Growth promotion, Health care, Immunodeficiency virus, Infection, Infectious diseases, Infectious diseases pharmacotherapy, Inhibitor, Intensive care, Intensive care patients, Intensive care unit, Invasive, Invasive aspergillosis, Invasive candidiasis, Mechanical ventilation, Meningitis, Mortality rate, Mrsa, Mrsa infections, Nrti group, Optimized background regimen, Parc mutation, Patient care, Pharmacotherapy, Pharmacotherapy volume, Placebo, Protease, Protease groups, Protease inhibitor, Pseudomonas aeruginosa, Pulmonary exacerbation, Randomized, Randomized trial, Regimen, Resistant organisms, Resistant pathogens, Respiratory distress syndrome, Risk factors, Ritonavir, Sars, Significant difference, Significant reduction, Streptococcus pneumoniae, Surveillance study, Susceptibility, Susceptibility testing, Unfavorable outcomes, Virologic failures, West nile virus infection.
Abstract
Most health care practitioners are challenged to maintain knowledge of contemporary practice issues in many therapeutic disciplines. Like many other areas, infectious diseases pharmacotherapy continues to evolve because of new information regarding disease epidemiology and new treatment options. Emerging infections and resistance further compound the need for information. To assist clinicians in identifying such important new information, we compiled a list of key references on infectious diseases pharmacotherapy published over the last 2 years.
Url:
DOI: 10.1592/phco.24.16.1586.50954
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000588
- to stream Istex, to step Curation: 000588
- to stream Istex, to step Checkpoint: 001F01
- to stream Main, to step Merge: 005C68
- to stream Main, to step Curation: 005822
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Key References in Infectious Diseases Pharmacotherapy</title><author><name sortKey="Drew, Richard H" sort="Drew, Richard H" uniqKey="Drew R" first="Richard H." last="Drew">Richard H. Drew</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:011A0BD1F59A3C2700BD57F5FB7224DB8D78DB14</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1592/phco.24.16.1586.50954</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-7MRQ8X1W-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000588</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000588</idno><idno type="wicri:Area/Istex/Curation">000588</idno><idno type="wicri:Area/Istex/Checkpoint">001F01</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F01</idno><idno type="wicri:doubleKey">0277-0008:2004:Drew R:key:references:in</idno><idno type="wicri:Area/Main/Merge">005C68</idno><idno type="wicri:Area/Main/Curation">005822</idno><idno type="wicri:Area/Main/Exploration">005822</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Key References in Infectious Diseases Pharmacotherapy</title><author><name sortKey="Drew, Richard H" sort="Drew, Richard H" uniqKey="Drew R" first="Richard H." last="Drew">Richard H. Drew</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><title level="j" type="alt">PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><biblScope unit="vol">24</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1586">1586</biblScope><biblScope unit="page" to="1593">1593</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-11">2004-11</date></imprint><idno type="ISSN">0277-0008</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>American college</term><term>Antibiotic</term><term>Antibiotic therapy</term><term>Antifungal</term><term>Antifungal susceptibility testing</term><term>Antifungal therapy</term><term>Antimicrobial</term><term>Antiretroviral</term><term>Antiretroviral agents</term><term>Article reviews</term><term>Asymptomatic bacteriuria</term><term>Aureus</term><term>Aureus infections</term><term>Azithromycin</term><term>Bacterial infections</term><term>Bacterial meningitis</term><term>Bacterial resistance</term><term>Candidiasis</term><term>Clinical pharmacy</term><term>Clinical trials</term><term>Complication rates</term><term>Critical care perspective</term><term>Cystic fibrosis</term><term>Dexamethasone</term><term>Diabetes mellitus</term><term>Disease epidemiology</term><term>Duke university</term><term>Fluoroquinolone</term><term>Fluoroquinolone resistance</term><term>Food animals</term><term>Fungal infections</term><term>Growth promotion</term><term>Health care</term><term>Immunodeficiency virus</term><term>Infection</term><term>Infectious diseases</term><term>Infectious diseases pharmacotherapy</term><term>Inhibitor</term><term>Intensive care</term><term>Intensive care patients</term><term>Intensive care unit</term><term>Invasive</term><term>Invasive aspergillosis</term><term>Invasive candidiasis</term><term>Mechanical ventilation</term><term>Meningitis</term><term>Mortality rate</term><term>Mrsa</term><term>Mrsa infections</term><term>Nrti group</term><term>Optimized background regimen</term><term>Parc mutation</term><term>Patient care</term><term>Pharmacotherapy</term><term>Pharmacotherapy volume</term><term>Placebo</term><term>Protease</term><term>Protease groups</term><term>Protease inhibitor</term><term>Pseudomonas aeruginosa</term><term>Pulmonary exacerbation</term><term>Randomized</term><term>Randomized trial</term><term>Regimen</term><term>Resistant organisms</term><term>Resistant pathogens</term><term>Respiratory distress syndrome</term><term>Risk factors</term><term>Ritonavir</term><term>Sars</term><term>Significant difference</term><term>Significant reduction</term><term>Streptococcus pneumoniae</term><term>Surveillance study</term><term>Susceptibility</term><term>Susceptibility testing</term><term>Unfavorable outcomes</term><term>Virologic failures</term><term>West nile virus infection</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Most health care practitioners are challenged to maintain knowledge of contemporary practice issues in many therapeutic disciplines. Like many other areas, infectious diseases pharmacotherapy continues to evolve because of new information regarding disease epidemiology and new treatment options. Emerging infections and resistance further compound the need for information. To assist clinicians in identifying such important new information, we compiled a list of key references on infectious diseases pharmacotherapy published over the last 2 years.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Drew, Richard H" sort="Drew, Richard H" uniqKey="Drew R" first="Richard H." last="Drew">Richard H. Drew</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005822 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005822 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:011A0BD1F59A3C2700BD57F5FB7224DB8D78DB14
|texte= Key References in Infectious Diseases Pharmacotherapy
}}
| This area was generated with Dilib version V0.6.33. |  |